Key facts
- Notable investors include Polar Light Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for TenaRx
- ·The full record, as it builds
Funding rounds
No funding rounds for TenaRx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TenaRx
Developer of selective CLK/DYRK kinase inhibitors designed to reprogram cellular fate and master-regulate immune, metabolic, and neurodevelopmental pathways. The company is currently operating in Stealth Mode.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2025
- Website
- tenarx.com/
- Ownership
- Privately Held (backing)
TenaRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TenaRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TenaRx in its N-PORT filings yet. We sweep new filings monthly.